Abstract
Aim
To investigate the efficacy of adalimumab in the cases with refractory non-infectious uveitis and evaluate retinal vascular leakage changes on ultra-widefield fundus fluorescein angiography.
Methods
Twenty-three patients with refractory uveitis were included in study.
Results
Forty-four eyes of 23 patients with non-infectious uveitiswere evaluated. Clinically active inflammation was present in 19 eyes (43.18%), while 25 (56.8%) were inactive. The mean drug burden was a 9.91 ± 3.78 (5–21) in baseline, 7.3 ± 4.25 at third and 8.0 ± 4.71 at sixth month (p = 0.022). The mean choroidal thickness was 256.65 ± 43.63 μm in baseline, 240.49 ± 36.73 μm at third and 224.81 ± 34.91 μm at sixth month (p ≤ 0.05). In terms of leakage extend, leakage was initially present in a mean of 2.95 ± 4.55 clock hours, 2.41 ± 3.91 at third and 1.76 ± 3.44 at sixth month (p < 0.001).
Conclusion
Adalimumab was found to be effective in establishing inflammation control by reducing drug burden, controlling retinal vascular leakage and choroidal inflammation in refractory uveitis.
Similar content being viewed by others
References
Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3):491–500
Chang JH, Wakefield D (2002) Uveitis: a global perspective. Ocul Immunol Inflamm 10(4):263–279
Diaz-Llopis M, García-Delpech S, Salom D et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351–361
Díaz-Llopis M, Salom D, Garcia-de-Vicuña C et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119(8):1575–1581
Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitisthat is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum 52(8):2478–2484
SantosLacomba M, MarcosMartín C, GallardoGalera JM et al (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33(5):251–255
Lee JT, Yates WB, Rogers S et al (2018) Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol 102(12):1672–1678
Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 18(3):226–232
Jaffe GJ, Dick AD, Brézin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932–943
Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516
Nussenblatt RB, Palestine AG, Chan CC et al (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92(4):467–471
Nussenblatt RB, Peterson JS, Foster CS et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5):764–770
Busch M, Bauer D, Hennig M et al (2013) Effects of systemic and intravitreal TNF-α inhibition in experimental autoimmune uveo retinitis. Invest Ophthalmol Vis Sci 54(1):39–46
Levy-Clarke G, Jabs DA, Read RW et al (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(3):785–96.e3
Hasegawa E, Takeda A, Yawata N et al (2019) The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med 42(2):79–83
Martín-Varillas JL, Calvo-Río V, Beltrán E et al (2018) Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease. Ophthalmology 125(9):1444–1451
Keino H, Okada AA, Watanabe T et al (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol 95(9):1245–1250
Mesquida M, Llorenç V, Fontenla JR et al (2014) Use of ultra-wide-field retinal imaging in the management of active Behçet retinal vasculitis. Retina 34(10):2121–2127
Leder HA, Campbell JP, Sepah YJ et al (2013) Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. J Ophthalmic Inflamm Infect 3(1):30
Pirani V, Pelliccioni P, De Turris S et al (2020) Intraocular inflammation control and changes in retinal and choroidal architecture in refractory non-infectious uveitis patients after adalimumab therapy. J Clin Med 9(2):510
Fabiani C, Vitale A, Emmi G et al (2017) Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36(1):183–189
Fabiani C, Sota J, Rigante D et al (2018) Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol 37(10):2805–2809
Sharma PK, Markov GT, Bajwa A et al (2015) Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis. Retina 35(12):2641–2646
Keino H, Okada AA, Watanabe T et al (2014) Long-termefficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye (London) 28(9):1100–1106
Vallet H, Riviere S, Sanna A et al (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74
Durrani K, Kempen JH, Ying GS et al (2017) Adalimumab for ocular inflammation. Ocul Immunol Inflamm 25(3):405–412
Kempen JH, Sugar EA, Jaffe GJ et al (2013) Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology 120(9):1852–1859
Ossewaarde-vanNorel J, Camfferman LP, Rothova A (2012) Discrepancies between fluorescein angiography and optical coherence tomography in macular edema in uveitis. Am J Ophthalmol 154(2):233–239
Funding
There is no funding support for this manuscuript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by Karadeniz Technical University, Faculty of Medicine, Ethic Council on 2020/209.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Uzlu, D., Köse, B., Akyol, N. et al. The evaluation of the efficacy of adalimumab in refractory non-infectious uveitis with ultra-widefield fundus fluorescein angiography. Int Ophthalmol 42, 2107–2116 (2022). https://doi.org/10.1007/s10792-021-02209-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-021-02209-x